Joint Diseases Market to Reflect Impressive Growth Rate by 2025

Joint disease is defined as any type of injury or inflammation or disease that affects human joints. Diseases of the joints could vary from acute to exceedingly chronic, unbearably painful or simply nagging and uncomfortable. It may be confined to one joint or may affect other parts of the skeleton. It can develop at any age; however, joint diseases are more prevalent in people aged between 40 and 65. Generally, women are at higher risk of developing joint diseases than men. However, it may vary with the type of joint disease. Joint diseases can be categorized into inflammatory joint disease, non-inflammatory joint diseases, and others.

In inflammatory joint disease, inflammation is principal set of symptom while in non-inflammatory joint disease, inflammation may present to some extent but it is not essential feature. Other joint diseases include congenital or hereditary abnormalities and secondary joint diseases (such as tumors of joints). Inflammatory joint diseases include bursitis, infectious arthritis, rheumatoid arthritis & allied disorders, collagen disease, and others. Non-inflammatory joint diseases include, traumatic joint diseases, and degenerative joint diseases. Treatment of joint diseases depend upon the cause and joint affected. Usually, treatment of joint diseases start with RICE (Rest, Ice, Compression, and Elevation) followed by conventional therapy, biologics, and sometimes surgery.

Request to View Brochure of Report –

https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=39521

The global Joint Diseases Market can be segmented based on joint disease type, treatment, and region. In terms of joint disease type, the global market can be categorized into inflammatory joint disease, non-inflammatory joint disease, and others. Based on treatment, the global joint diseases market can be classified into medication (non-steroidal anti-inflammatory drugs, analgesic, steroids, biologic therapy, and immunosuppressive drug), therapy (physiotherapy and hydrotherapy), and surgery (joint replacement surgery). Rise in incidence and prevalence of various joint diseases, increased research and development expenditure, growing awareness among people, surge in geriatric population, and high number of joint injuries contribute to the growth of the global joint diseases market. However, currently available therapeutic options are effective at managing and preventing joint disease progression, the challenges of treating the joint diseases lie in the unpredictable responses of each patient, representing one of the biggest unmet needs in the global joint diseases market.

Geographically, the global joint diseases market can be segmented into five regions: North America, Europe, Latin America, Asia Pacific, and Middle East & Africa. North America is anticipated to dominate the market, followed by Europe. High incidence of joint diseases, rise in geriatric population, growing awareness among people, surge in research and development expenditure, strong clinical pipeline, and well-established health care infrastructure propel the joint diseases market in North America.

The market in Asia Pacific is anticipated to expand at a high CAGR during the forecast period. This is attributed to large patient base, increase in government initiatives, and developing health care infrastructure in India and China. The market in Latin America and Middle East & Africa is anticipated to grow during the forecast period, owing to rise in investments by key players in these regions and increase in prevalence of joint diseases.

Leading players in the global joint diseases market include AbbVie, Pfizer Inc., Bristol-Myers Squibb, F. Hoffmann-La Roche Ltd., GlaxoSmithKline, AstraZeneca plc, Astellas Pharma, Johnson and Johnson, Amgen, Novartis International AG, Sanofi SA, and Daiiachi Sankyo.

Enquiry for discount on this report –

https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=39521

About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

 

US Office Contact

90 State Street, Suite 700

Albany, NY 12207

Tel: +1-518-618-1030

USA – Canada Toll Free: 866-552-3453

Email: sales@transparencymarketresearch.com

Website: http://www.transparencymarketresearch.com